It is widely believed that prolonged mechanical ventilation imposes a heavy economic burden on patients, healthcare systems, and society. American scholar Zilberberg estimates the aggregate bill for their hospital care alone would be over $64 billion annually after adjusting for the age and inflation of PMV patients across the country [19]. Based on our results, the economic burden of PMV among AAAD patients was considerably high with a median hospitalization cost was up to $12,408.28 in China, and each of them paid $4,970.28 for additional costs. To our knowledge, this study was the first domestic study to quantify the direct economic burden among AAAD patients associated with PMV. It should be reminded that the high level of economic burden caused by PMV among these patients for the local government and hospitals, this study provided solid evidence for the importance of future PMV Intervention and management.
From our results, the median total hospitalization costs per PMV patients were $12408.28 compared with those of the non-PMV group, which were $7438.00. In developed countries, Canadian scholar Zilberberg et al [20] showed that the median hospitalization cost of PMV patients was as high as $55,014, while in the non-PMV group it was $20,120. The results of Vallabhajosyula et al [21] showed that the long-term use of MV with acute myocardial infarction patients costs $247,169 ± 227,047, and this cost is 3 times than that of non-PMV patients. What’s more, PMV will also increase the financial burden of patients one year after discharge. In Hill et al's [9] study, it was found that the median cost of patients who received PMV was $42,784, while the median cost of patients who did not receive PMV was $13,005. In contrast, the disposable income of per capita residents in Fujian Province, Canada, and the United States were $4,451.56, $45,100, and $57,700 in 2017, respectively [22, 23]. These differences could be attributable to the level of national economic development, various health insurance systems, differential epidemiology, and objects or methods used between different studies. In short, whether in developed or developing countries, PMV will bring a huge economic burden to patients.
In our study, PMV developed in 30.6% of AAAD patients, and each of them paid $4,970.28 for additional costs, the extra cost could be partly due to some interventions. For example, they may need a tracheostomy and place a feeding tube for continuous care. They were confronted with ventilator-associated complications (such as ventilator-associated pneumonia), but also at increased risk of other hospital complications, such as Clostridium difficile infection (CDI), which caused disproportionate distress to patients. Besides, PMV patients are more likely to visit county-level medical institutions or take healthcare services home [24, 25]. In brief, PMV patients represent unique critically ill patients who consume disproportionate medical resources, they shoulder more than 60% of all costs related to the entire MV population [19]. It shows that a moderate reduction in MV and hospital stay can also limit medical expenditures and hospital economic losses in different proportions. For example, daily spontaneous awakening trials (SAT), a pilot project funded by the Centers for Disease Control and Prevention adopted these technologies, which not only nearly doubled the pairing of SAT but also reduced the number of MV, ICU, and hospital stays [19]. Clinical intervention based on Six Sigma reduced the median length of stay by 27% and the direct cost by 27% in PMV patients [26].
Another unique point of our research is the spread of cost categories. Through stratified analysis by costs, the western medicine was the highest direct economic burden amount to an average of $3183.23 per patient, followed by blood transfusion and materials, the increased cost per patient was $250.81 and $207.43. Others studies have shown that western medicine accounted for approximately 36.9% and 37.9% of medical costs and constituted a major of patients' additional medical costs in China [27], it demonstrates that the usage of western medicine was a general phenomenon. While the cost of surgery, treatment, and nursing, which is a good reflection of labor value, is lower than the basic cost, particularly the nursing cost is even significant in the total hospitalization costs. In our study, the cost of treatment, examination, Laboratory, and nursing are statistically significant in the two groups of patients, reflecting that the PMV group paid more extra costs than the MV group. However, it only accounts for a small part of the total economic burden.
Furthermore, our team developed implements triple-branched stent-graft placement and applied to all AAAD patients [28], there was no statistically significant difference in surgical and material costs between the two groups. It’s not difficult to see that medical insurance reimburses almost all the surgical fees, a significant proportion of patients still pay the material costs. It is worth mentioning that the material cost is second only to the cost of western medicine in the total cost. The median material cost of the MV group is $1871.73, and the PMV group is $2079.16. This indicated that although China initiated a new medical reform to reduce the cost of medicines to increase labor costs in 2010. However, this issue needs to be further resolved by relevant government agencies and personnel. The future medical reform may try to increase the scope of reimbursement of material cost, and when purchasing high-value medical consumables, under the premise of ensuring medical quality, comparative procurement should be carried out based on the principles of reasonable prices and clinical needs. These measures may be expected to reduce the economic burden of AAAD patients.
Due to the same surgery, which reduces postoperative hospital mortality [16] and postoperative complications [29]. Still, the impact of extracorporeal circulation and poor coagulation function of patients, nearly all patients required blood transfusions postoperatively. According to our research, the cost of blood transfusions among PMV groups paid an extra $250.81 to the MV group. The same conclusion was drawn in Newcomb’s study [30], post-cardiac bleeding contributes to increased hospital costs by 1.76 times. Blood is a limited resource. Therefore, under the context of the current medical reimbursement system, blood products, as a nutrition and health care category, are not included in the medical reimbursement. However, governments introduce new national policies to reduce the blood transfusion for blood donors [31], which will save a large number of patients from the huge economic burden.
The findings also suggest that PMV can cause an increase significantly in the hospital and ICU LOS among patients. It is estimated that PMV patients with AAAD were prolonged by five days both in hospital and ICU LOS. Similar conclusions have been confirmed in several other studies [10–12]. It is well-known that hospitalization costs increased gradually with the increase of hospitalization days, and the relationship between costs and LOS has been confirmed in many studies. Previous studies have displayed those additional costs related to hospital LOS were the main drivers of medical costs [33–35]. Prolonging the LOS not only increases the direct economic burden but also the indirect economic burden, it is due to patients have to be absent from work. If the exact indirect economic burden is needed, the rigorous economic data requires a detailed manual calculation of specific time and resource usage and cost, which is not feasible at the scale of such study, thus, we did not evaluate the indirect economic burden among these patients.
We acknowledge several limitations in this study. First of all, all patients were recruited from a single hospital in southeast China, the findings of this study may not be extended to other hospitals with different regions and economic conditions, Thus, our findings have limited generalizability. Secondly, given the small sample size may be biased of the results. Given this, future studies with an increased sample size should be performed to improve the accuracy of results from different hospitals or even different countries. Third, due to the limited information, we were unable to evaluate the indirect economic burden related to extended sick leave duration. Thus, further study and the collection of more data (a type of job, monthly salary) are required to assess the indirect economic burdens. Finally, we did not conduct follow-up and evaluate unplanned readmission for AAAD patients after discharge from the hospital, which implies that we are likely to have underestimated the actual additional costs.